Silence Therapeutics Begins Phase I Trial of Cancer Rx, Posts Higher '08 Losses | GenomeWeb

Silence Therapeutics last month announced that it had begun dosing patients in a phase I study of its siRNA-based solid tumor drug Atu-027.

Separately last month, the British company also reported its financial results for 2008, posting a 45 percent increase in its net loss on lower revenues and higher costs.

Atu-027 comprises modified, blunt-ended siRNA that target PKN-3, a protein kinase that company researchers have linked to tumor growth and metastases, and formulated with a mixture of cationic and fusogenic lipids.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.